Stenabolic comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2025-11-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
Stability depends on physical form, temperature, light exposure, and solvent. Solid SR9009 is generally stored cold and dry, with protection from light to limit degradation. Dimethyl sulfoxide stocks are common for laboratory work, but repeated freeze-thaw cycles can reduce compound integrity. Aqueous solutions may be less stable than organic stocks, and the ethyl ester in the structure can be susceptible to hydrolysis under certain conditions. Researchers typically validate storage conditions and recheck purity before quantitative experiments, especially when using archived material.
Regulatory treatment of SR9009 varies by country and region. It is not approved as a pharmaceutical, and several jurisdictions restrict its sale for human consumption. Some authorities classify it as a research chemical, a prescription-only substance, or a prohibited performance-enhancing agent in sport. Purchasers may encounter certificates of analysis, but these documents do not guarantee identity, purity, or legality. In research settings, institutional safety reviews and controlled procurement help ensure that materials are handled under appropriate oversight. The absence of harmonized rules means that legal status can change and requires verification.
Analytical identification of SR9009 typically relies on liquid chromatography coupled with tandem mass spectrometry. In biological samples, researchers first separate the compound from matrix components using protein precipitation, liquid-liquid extraction, or solid-phase extraction. High-performance liquid chromatography with ultraviolet detection and nuclear magnetic resonance spectroscopy can support structural confirmation of reference materials. Because SR9009 is a small, relatively lipophilic molecule, reverse-phase columns and acidic mobile phases are common. Laboratories often include isotope-labeled internal standards to improve quantification and to correct for ion suppression.
| Property | Value | Notes |
|---|---|---|
| Common name | SR9009 | Also marketed informally as Stenabolic |
| Chemical class | Synthetic REV-ERB agonist | Binds REV-ERBα and REV-ERBβ |
| Molecular formula | C24H30ClN3O4S | Approximate molecular weight 492 g/mol |
| CAS Registry Number | 1379686-30-2 | Identifier for the parent compound |
| Regulatory status | Not approved for human use | Prohibited in sport by WADA |
Several misconceptions surround SR9009. It is often described as a SARM, a steroid, or an exercise pill, but its known target is the REV-ERB receptor family. Rodent studies have examined exercise capacity and metabolic markers, yet human outcomes remain unproven. Oral bioavailability appears low in animals, and human pharmacokinetics are not well characterized. Online products may contain impurities or different compounds, so identity and purity testing are important for research use.
Analytical chemists detect SR9009 with liquid chromatography-tandem mass spectrometry, commonly abbreviated LC-MS/MS. Sample preparation may involve protein precipitation, liquid-liquid extraction, or solid-phase extraction before analysis. Laboratories can target the parent compound or its metabolites, depending on the matrix and the purpose of testing. Anti-doping methods require sensitive and specific assays because concentrations in biological samples can be low. Reference standards and validated methods are essential for reliable identification and quantification.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Because REV-ERB receptors are core clock components, SR9009 has been examined for effects on daily rhythms as well as metabolism. Research has explored whether the compound can shift or reinforce circadian gene expression in tissues such as liver and muscle. Some studies report improved metabolic markers in obese or diabetic mice, while others show context-dependent responses. Questions remain about which effects are direct, which are secondary to timing, and how they might differ across species.
SR9009 is a synthetic small molecule studied as an agonist of REV-ERB nuclear receptors. REV-ERB alpha and REV-ERB beta help regulate circadian rhythms and metabolic gene expression. In laboratory research, SR9009 has been used to probe how these receptors affect skeletal muscle, liver, and adipose tissue. The compound was identified in academic drug-discovery work and is often described in scientific literature by its chemical name and research code. It is not an approved medicine, and human clinical data remain limited or absent.
SR9009 binds REV-ERB receptors and alters their repressive activity on target genes. This action can change transcription of genes involved in lipid handling, glucose metabolism, and mitochondrial function. In rodent studies, treated animals have shown changes in muscle oxidative capacity and exercise performance, though effects vary by dose, duration, and model. The precise molecular steps connecting receptor binding to whole-body outcomes are still an active area of investigation. Findings in animals do not automatically translate to humans.
Research interest in SR9009 grew from studies of circadian biology and metabolic disease. Preclinical reports describe effects on exercise capacity, muscle metabolism, and blood lipid levels in rodents, but these findings come from controlled laboratory settings. The compound has low oral bioavailability in animals, which limits systemic exposure after swallowing. Investigators often use injected routes in experiments to achieve measurable plasma concentrations. Human clinical data are sparse, no approved therapeutic product exists, and whether animal effects translate to humans remains an open question.
Regulatory and sporting contexts treat SR9009 as a prohibited substance in many elite competitions. Its presence on banned lists reflects concerns about performance enhancement and unknown long-term safety. Analytical chemists have developed methods to detect the parent compound and its metabolites in urine and blood. Literature discussions distinguish between in vitro potency, animal pharmacology, and anecdotal human reports. The latter are difficult to verify because products sold online may lack purity or contain different compounds.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. These receptors help regulate circadian rhythms, lipid metabolism, and inflammatory gene expression. In cell and animal experiments, SR9009 alters transcription of clock-controlled genes and metabolic pathways. The compound is not a hormone and does not resemble classical steroid structures. Its activity depends on binding to the ligand-binding domain of REV-ERB, where it can modify corepressor recruitment.
== Applications in antimicrobial development == Over the last twenty years, there has been increasing interest in leveraging inteins for antimicrobial applications. Intein splicing is found exclusively in unicellular organisms, with a particularly high abundance in pathogenic microorganisms. Furthermore, inteins are commonly found within housekeeping proteins and/or proteins involved in the survival of the organism within a human host. Post-translational intein removal is necessary for the protein to properly fold and function. For example, Gaëlle Huet et al. demonstrated that in Mycobacterium tuberculosis, unspliced SufB prevents the formation of the SufBCD complex, a component of the SUF machinery. As such, the inhibition of intein splicing may serve as a powerful platform for the development of antimicrobials. Current research on intein splicing inhibitors has focused on developing antimycobacterials (M. tb. has three intein-containing proteins), as well as agents active against pathogenic fungi Cryptococcus and Aspergillus. Cisplatin and similar platinum-containing compounds inhibit splicing of the M. tb. RecA intein through coordinating to catalytic residues. Divalent cations, such as copper (II) and zinc (II) ions, function similarly to reversibly inhibit splicing. However, neither of these methods are currently suitable for an effective and safe antibiotic. The fungal Prp8 intein is also inhibited by divalent cations and cisplatin through interfering with the catalytic Cys1 residue. In 2021, Li et al.
== Intellectual property == A2 Corporation licensed patents filed in the 1990s by the New Zealand Dairy Board and filed its own patents on genetic tests to determine what form of beta-casein cows produce in milk and concerning potential adverse health consequences of standard milk. By 2012 A2 Corporation had developed a worldwide suite of intellectual property, including trademarks, trade secrets, and patents covering products, the genetic test and methods to develop A1 protein-free producing herds, as well as methods to check the protein content and fatty acid content of milk, dietary supplements with A2 beta-casein, and even therapeutic uses of A1 protein-free products. The a2 Milk Company continues to develop a portfolio of intellectual property, including trademarks and patents. The a2 Milk Company also invests in targeted research and development associated with the benefits of the A2 protein. In September 2017, it was reported that the a2 Milk Company got approval to keep selling its products in China.
Krebs (1900–1981), German-British biochemist, Nobel Prize in Physiology or Medicine (1953)for work on metabolic cycles Harold Kroto (1939–2016), English chemist, 1996 Nobel Prize in Chemistry for discovery of fullerenes Richard Kuhn (1900–1967), 1938 Nobel Prize in Chemistry for work on carotenoids and vitamins Eugenia Kumacheva (PhD 1986), Ukrainian-Canadian chemist with work on fundamental and applied polymers science, nanotechnology, microfluidics, and interface chemistry Theodore Kuwana, (1931–2022), American chemist, founder of the field of spectroelectrochemistry
=== Intestinal mucosa === The intestinal mucosa is the innermost mucous membrane of the gastrointestinal tract. It surrounds the cavity (lumen) of the tract and comes into direct contact with digested food (chyme). The mucosa is made up of three layers:
Sources: en.wikipedia.org
At the 2015 China Victory Day Parade, Xi announced a reduction of 300,000 troops from the PLA, bringing its size to 2 million troops. Xi described this as a gesture of peace, while analysts have said that the cut was done to reduce costs as well as to modernize the PLA. In November 2015, the Central Leading Group for Military Reform announced extensive reforms in the PLA called Deepening National Defense and Military Reform. In 2016, Xi reduced the number of theater commands of the PLA from seven to five. He also abolished the four autonomous general departments of the PLA, replacing them with 15 agencies directly reporting to the CMC. Two new branches of the PLA were created under his reforms, the Strategic Support Force and the Joint Logistics Support Force. PLA Second Artillery Corps was upgraded to the PLA Rocket Force. In March 2016, the CMC announced the abolishment of paid services by the PLA and the People's Armed Police (PAP) by 2019, meaning activities like military-run hospitals and hotels open to the public. On 21 April 2016, Xi was named commander-in-chief of the country's new CMC Joint Operations Command Center. In 2018, the PAP was placed under the sole control of the CMC; it was previously under the joint command of the CMC and the State Council through the Ministry of Public Security. The PLA went through further extensive reforms in 2024; the Strategic Support Force was dissolved and the Aerospace Force, the Cyberspace Force and the Information Support Force was established as arms of the PLA, joining the Joint Logistics Support Force.
Patient-centric definitions, generally independent of changes in technology Concepts with references to established international definitions Definitions specifying measurement units (with preference for SI) and measured properties Consistent with the principles outlined in the International Vocabulary of Metrology (VIM) and Vocabulary for Nominal Properties and Nominal Examinations (VIN) Broad membership of guiding NPU committee with extensive expertise in the biological and chemical sciences and the principles of nomenclature.
Beta blockers have a variety of drug interactions. An example is that various beta blockers including propranolol, carvedilol, nebivolol, timolol, and metoprolol are metabolized by the cytochrome P450 enzyme CYP2D6 and may be potentiated by CYP2D6 inhibitors like fluoxetine, paroxetine, duloxetine, and bupropion. This may increase the risk of adverse effects like bradycardia and hypotension.
=== Medical === Dihydromorphine is used for the management of moderate to severe pain such as that occurring in cancer; however, it is less effective in treating neuropathic pain and is generally considered inappropriate and ineffective for psychological pain.
== History == The facility was created by 2014, with funding from the Canada Foundation for Innovation and the Ontario Research Fund. It is located in the University of Ottawa's Advanced Research Complex. It replaced the IsoTrace facility at the University of Toronto and cost around 10 million dollars. In 2017, the laboratory will host the 14th annual Accelerator Mass Spectrometry conference.
Sources: en.wikipedia.org
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.
No. SR9009 has not been approved as a therapeutic drug in the United States, European Union, or other major markets. Human safety and efficacy data are very limited. Its presence in consumer products does not imply regulatory approval.
The World Anti-Doping Agency lists SR9009 as a prohibited substance because it can alter gene expression and metabolic pathways relevant to performance. The ban applies at all times, not only during competition. Detection relies on laboratory methods such as mass spectrometry.
The most common approach is liquid chromatography-tandem mass spectrometry, often after extraction from blood, urine, or tissue. Ultraviolet detection and nuclear magnetic resonance spectroscopy are used mainly for reference material characterization. Isotope-labeled internal standards improve accuracy.